ClinicalTrials.gg
Active, not recruitingNCT06516068Updated Jul 16, 2025

A Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy

A Phase 2 interventional study of HRS-1893 in Obstructive Hypertrophic Cardiomyopathy, sponsored by Shandong Suncadia Medicine Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-07-16.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies in Cardiomyopathy, Hypertrophic with a site in China — 30 open to participants now, 43 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · China.

Enrollment
28th of 39
42 · median 84
Started
2024
with 9 others
Phase 2
4 of 71
2 open now
Primary completion
2024-11
later than 9 of 42 live
Registered
44th of 71
by date
Lead sponsor
7 of 71
Shandong Suncadia Medicine Co., Ltd.

Among the 71 studies in Cardiomyopathy, Hypertrophic with a site in China, this one is the 28th largest by enrollment of the 39 interventional ones that give a count, is one of 10 that started in 2024, is one of 4 in phase 2, reaches primary completion later than 9 of the 42 other live ones, and was the 44th registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

30 of the 71 studies in Cardiomyopathy, Hypertrophic with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Cardiomyopathy, Hypertrophic with a site in China, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the efficacy, and safety of HRS-1893 for obstructive hypertrophic cardiomyopathy

03

Conditions studied

  • Obstructive Hypertrophic Cardiomyopathy
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-85 years old, gender unlimited;
  2. The diagnosis was obstructive hypertrophic cardiomyopathy.
  3. Echocardiographic laboratory tests showed ≥60%;
  4. No previous left ventricular systolic dysfunction at any time (LVEF \< 45%);
  5. Understand the study procedure and sign the in person, willing to strictly follow the clinical study protocol to complete the study.

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected invasive, genetic or storage diseases (e.g. Noonan syndrome, Fabre's disease, amyloidosis) that cause cardiac hypertrophy (similar to oHCM);
  2. Previous left ventricular systolic dysfunction at any time in the clinical course ( \< 45%);
  3. Previous history of aortic stenosis or subaortic fixed stenosis;
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    HRS-1893

    Drug: HRS-1893

Interventions

06

What researchers measure

Primary outcomes

  1. The subjects' left ventricular outflow tract pressure gradient (Valsalva LVOT-G) was assessed for changes from the baseline after performing the Valsalva maneuver

    Time frame: After 12 weeks of HRS-1893 treatment

Secondary outcomes

  1. Change in peak oxygen uptake (pVO2) and carbon dioxide ventilation equivalent (VE/VCO2)

    Time frame: Baseline to Week 12

  2. Change in LVEF

    Time frame: Baseline to Week 12

  3. Change in LVOT-VTI

    Time frame: Baseline to Week 12

  4. Change in LV-FS

    Time frame: Baseline to Week 12

  5. Change in LV-GLS

    Time frame: Baseline to Week 12

  6. Change in Rest LVOT-G

    Time frame: Baseline to Week 12

  7. Change in Valsalva LVOT-G

    Time frame: Baseline to Week 12

  8. Change in cardiac troponin

    Time frame: Baseline to Week 12

  9. Change in NT-proBNP

    Time frame: Baseline to Week 12

  10. Change in Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS)

    Time frame: Baseline to Week 12

  11. Proportion of participants with ≥ 1 class improvement in NYHA Functional Class

    Time frame: Baseline to Week 12

  12. Incidence and severity of any adverse events (AESI, SAE, TRAE, TEAE)

    Time frame: Through study completion, an average of 68 weeks

  13. plasma concentration of HRS-1893

    Time frame: Through study completion, an average of 68 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Nov 2024, 3 months.

Of 20 phase 2 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 43. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2024
First posted
Jul 23, 2024
StartActual
Aug 11, 2024
Primary completionActual
Nov 18, 2024
CompletionEst.
Aug 2025
Last update
Jul 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06516068
Responsible party
Sponsor
First posted
Jul 23, 2024
Start date
Aug 11, 2024
Primary completion
Nov 18, 2024
Completion
Aug 2025 (estimated)
Last update
Jul 16, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-1893

Start the discussion